The Five Questions US Ambulatory Surgery Center Operators Should Ask a Technology Consultant Before Funding a Custom Perioperative Platform

This article is part of our series on Custom Ambulatory Surgery Center Platform Development for US ASC Operators: Building a Block Scheduling, Implant Tracking and Perioperative Documentation System

Introduction: Five Questions for a Board That Includes Surgeons

A decision to fund a custom platform at an ambulatory surgery center is made by a board that usually includes its surgeons. That shapes what a conversation with an ASC technology consultant has to produce.

Those partners will want to know what the platform does for their room time, what it does to their documentation burden, and why the money is not being distributed instead.

Five questions filter partners for custom software development and for the surgeon scheduling and patient portals around it. They cover the utilization arithmetic, the traceability test, the clinical boundary, the regulatory maintenance obligation and the honest ASC software build vs buy position.

The surgeon scheduling and patient portals are the web application development side of that build. The third matters most, because a partner who is unclear about where software stops and clinical judgment begins should not be building an operating room.

None requires technical knowledge to ask or evaluate. Pre-build scoping is the decision layer of the full custom ASC platform development guide.

Question One: What Is Our Room Time Actually Worth?

This is a question about the center that reveals the partner, because anybody proposing a platform here should have asked it before proposing anything.

A good ASC technology consultant wants the arithmetic first. That means available room hours, used hours by the center’s stated method, contribution per case by specialty, and what an additional case per room per day would be worth. Then the gap between allocated block and used block, and what proportion of unused time was released early enough to be filled.

What they should do with it is show the business case in the center’s own numbers. They should also be honest that some unused time is not recoverable, because a surgeon’s slow quarter or a genuinely thin market is not a software problem.

A weak answer moves straight to documentation features, which are more interesting to demonstrate and do not increase revenue.

The follow-up worth asking: what proportion of that unused time do they think is addressable, and by what mechanism? An honest partner will distinguish coordination waste from demand. Coordination waste is software’s to fix; demand is not.

Question Two: Show Me How You Would Answer a Recall

Ask for the walkthrough, not the assurance.

A manufacturer notifies the center that a lot of an implanted device is being recalled. Produce every patient who received one.

A biological indicator returns positive for a load run three days ago. Produce every set in that load, every case each was used on, and every patient affected.

A good partner describes the chain concretely: scanning at the point of use, patient linkage established at the case, individually identified instrument sets, load composition recorded, and retrieval in both directions tested at acceptance.

The phrase to listen for is that they would test it. A traceability chain nobody has exercised is a chain nobody knows the state of.

A weak answer describes storing implant information for inventory and billing, which is a different capability that happens to share a data field. And a partner who does not immediately understand why the biological indicator scenario is a patient safety event has not worked in a surgical setting.

The obligations these questions are designed to surface are set out in CMS ASC Conditions for Coverage, ASCQR Quality Reporting Deadlines, Accreditation Survey Records, UDI Implant Traceability and HIPAA.

Question Three: Where Does Your Software Stop?

This is the question that should decide whether the conversation continues.

Ask directly: does anything in the proposed platform assess a patient, score anything clinical, determine discharge readiness, or recommend whether a case should proceed?

The correct answer is no, without hedging, and a partner who understands the setting will explain why unprompted. Clinical determinations belong to licensed clinicians who carry the responsibility for them.

Software that assesses a patient has entered territory with its own regulatory framework. It also places the center’s clinicians in a position where a system’s output competes with their judgment.

The related boundary is safety practice. Ask what the platform does with the timeout and the count. The answer should be that it records them as performed.

Any suggestion of timing them, scoring compliance speed or streamlining them should end the conversation, because that is pressure applied exactly where pressure causes harm.

A partner who proposes discharge scoring or count reconciliation as features has not understood what they are building, however impressive the demonstration looks. The same test applies to controlled substance discrepancies, which belong with accountable people rather than an algorithm.

Question Four: Who Maintains the Regulatory Content?

This question surfaces the cost most often left out of a proposal, and it is permanent rather than one-time.

Quality measures are added, retired and respecified on an annual cycle. Conditions and accreditation standards are revised. Payer requirements shift, and device and tissue requirements develop.

A platform encoding any of that as logic rather than maintained configuration will be wrong within two years. Being wrong about a quality measure means a reporting failure with a payment consequence, discovered long after it could be corrected.

So ask who does that work, what it costs annually, and what happens if the center’s build partner is no longer engaged.

A good answer treats regulatory content as configuration maintained by someone with named responsibility and a budget line. A weak one describes it as updates included in support, which is a promise nobody has costed.

Ask, too, how measure changes would reach the platform: as configuration a named person updates, or as a development project each year.

This is also the strongest argument for a purpose-built platform, and an ASC technology consultant who acknowledges that is being straight with you.

Question Five: Should We Actually Build This?

Ask it plainly. The answer is informative whichever way it goes.

Purpose-built ASC platforms exist and are established. They cover scheduling, clinical documentation, anesthesia records, materials, sterile processing and revenue cycle, with the regulatory content maintained by people who do it across many centers.

For most single-center operators, one of those is the right answer. A partner who cannot name them, or dismisses them without testing against the center’s actual requirements, is not advising.

A good answer sounds like this: here is what those platforms do well, here is what your center needs that they handle poorly, here is how we would test that, and here is what the narrower project would be if the gap is real.

The narrower project is frequently the right one: retaining a platform for clinical documentation and regulatory content while building the scheduling, surgeon experience or analytics layer where the operator actually differentiates.

A partner willing to reach that conclusion is one worth engaging when a build is warranted. The estimate a consultant should be able to defend is detailed in Custom ASC Platform Development Cost.

Reading the Pattern

Taken together, the five answers show whether a partner understands surgical care or sees a generic scheduling and records problem.

The pattern to look for: they want the utilization arithmetic before proposing anything, walk through the recall scenarios concretely and offer to test them, and are unambiguous that clinical determinations belong to clinicians. They treat regulatory maintenance as a named permanent cost, and will say when the center should buy rather than build.

The pattern to walk away from: enthusiasm for documentation screens, traceability described as inventory, discharge scoring or count reconciliation offered as features, timeout compliance timed as a metric, regulatory updates described as included, and no engagement with the purpose-built platforms.

One more signal is worth weighing: a partner who asks to observe a turnover. What consumes those minutes is where the operational value is.

Final Thoughts

Operators who ask these five before funding anything filter effectively without technical knowledge, because each question is about the center rather than the software.

The third is worth asking of a platform vendor as well as a development partner such as NewAgeSysIT, since the clinical boundary matters whoever built the system, and a board that includes surgeons will want the answer.

If you are weighing a custom perioperative platform, running a test recall against a real implant lot before any vendor conversation gives you a question you already know the answer to. Learn more about digital transformation solutions from one of the leading AI software companies in the United States.

FAQ